Aligos Therapeutics, Inc. (ALGS)
2.15
-0.42
(-16.34%)
USD |
NASDAQ |
Nov 11, 16:00
2.09
-0.06
(-2.79%)
After-Hours: 19:59
Aligos Therapeutics Gross Profit Margin (Quarterly) : 91.25% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 91.25% |
| June 30, 2026 | 99.08% |
| March 31, 2026 | 87.77% |
| December 31, 2025 | -52.07% |
| September 30, 2025 | 70.31% |
| June 30, 2025 | 73.16% |
| March 31, 2025 | 37.62% |
| December 31, 2024 | -6.68% |
| September 30, 2024 | 47.44% |
| June 30, 2024 | 42.51% |
| March 31, 2024 | 31.64% |
| December 31, 2023 | 71.09% |
| Date | Value |
|---|---|
| September 30, 2023 | 78.98% |
| June 30, 2023 | 88.83% |
| March 31, 2023 | 69.00% |
| December 31, 2022 | 74.64% |
| September 30, 2022 | 77.93% |
| June 30, 2022 | 75.93% |
| March 31, 2022 | 61.77% |
| December 31, 2021 | 0.00% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Agenus, Inc. | 98.37% |
| Amgen, Inc. | 73.09% |
| Anika Therapeutics, Inc. | 61.57% |
| BioCryst Pharmaceuticals, Inc. | 98.99% |
| Imunon, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -165.4% |
| Return on Assets | -87.81% |
| Return on Invested Capital | -143.2% |
| Profit Margin (Quarterly) | -761.9% |
| Operating Margin (Quarterly) | -763.0% |
| Return on Net Operating Assets | -569.5% |